Head-to-head · WeighScore
Onyx Weight Loss vs Vita Bella
The verdict
Vita Bella takes it — 64.9/100 to 58.8/100.
Vita Bella grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Vita Bella is a Nevada-based telehealth membership platform (Vita Bella Health, LLC) that offers compounded GLP-1 weight-loss medications alongside hormone therapy, peptides, sexual-wellness and anti-aging…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Onyx Weight Loss | Vita Bella |
|---|---|---|
| WeighScore | 58.8/100 | 64.9/100 |
| Grade | C | C |
| Scorecard rank | #358 | #238 |
| Semaglutide | $228/mo (starting dose, compounded) | Not disclosed |
| Tirzepatide | $280/mo (starting dose, compounded) | $159/mo (2.5 mg dose, plus a separate fee, compounded) |
| Coverage | 8 states | 46 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #358 · C
Strengths
- Competitive entry pricing: semaglutide from $228/mo and tirzepatide from $280/mo with medication + supplies included
- Nurse-practitioner-led care: founder Tasha Vangile FNP-C (20+ years) and Stephanie Robison APRN-CNP (27 years experience)
- Low-cost $99/mo GLP-1 microdosing option for patients who prefer a gradual titration start
- Strive Pharmacy partnership implies compounded 503A-quality supply chain from a known pharmacy
- Multi-modal clinic: GLP-1 + peptides + HRT + nutrition coaching available under one provider team
Where it loses points
- Only 8 states (NC, CO, ME, VT, VA, IA, NH, PA) — excludes the majority of the US
- No LegitScript certification; credentialing evidence limited to local 2025 Best of Iredell award
- Specific drug names (semaglutide/tirzepatide) never stated on website; compounded status inferred, not disclosed
- Labs not included or mentioned; no baseline bloodwork protocol published
- Pricing shown as 'Starting at' with no dose-escalation tier pricing disclosed publicly
Graded #238 · C
Strengths
- Offers both compounded semaglutide (from $109/mo) and tirzepatide (from $159/mo) at member pricing, with supplies and a B-6 add-in included
- Genuine LegitScript-certified website (seal #4395819) and a clearly disclosed legal entity, Vita Bella Health, LLC (Nevada)
- Broad access: care published for 46 states plus Washington, D.C., and HSA cards are accepted
- Fully remote telehealth with video provider consults and quarterly provider check-ins included in the membership
- Medications dispensed by US FDA-inspected compounding pharmacies; ondansetron for nausea provided at no extra charge
Where it loses points
- Advertised $109-$159 medication prices require a separate $129/mo membership plus a one-time $99 consult, pushing true cost to ~$238-288/mo
- Three-month minimum commitment before it renews month-to-month; no refunds on medications and all sales are final
- Compounding pharmacy partners are not named anywhere on the site — a transparency gap
- Compounded semaglutide and tirzepatide are not FDA-approved; only the dispensing pharmacies are described as FDA-inspected
- Disputes are subject to binding arbitration with a class-action waiver, governed by Nevada law (Las Vegas jurisdiction)
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.